Annual Cash & Cash Equivalents
$50.18 M
-$17.86 M-26.25%
30 April 2024
Summary:
PharmaCyte Biotech annual cash & cash equivalents is currently $50.18 million, with the most recent change of -$17.86 million (-26.25%) on 30 April 2024. During the last 3 years, it has risen by +$47.98 million (+2178.73%). PMCB annual cash & cash equivalents is now -41.24% below its all-time high of $85.40 million, reached on 30 April 2022.PMCB Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$32.64 M
-$17.54 M-34.96%
31 July 2024
Summary:
PharmaCyte Biotech quarterly cash and cash equivalents is currently $32.64 million, with the most recent change of -$17.54 million (-34.96%) on 31 July 2024. Over the past year, it has dropped by -$40.79 million (-55.55%). PMCB quarterly cash and cash equivalents is now -62.46% below its all-time high of $86.94 million, reached on 31 October 2021.PMCB Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PMCB Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -26.3% | -55.5% |
| 3 y3 years | +2178.7% | -62.5% |
| 5 y5 years | +9638.0% | +10000.0% |
PMCB Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -41.2% | +2178.7% | -62.5% | at low |
| 5 y | 5 years | -41.2% | +9638.0% | -62.5% | >+9999.0% |
| alltime | all time | -41.2% | >+9999.0% | -62.5% |
PharmaCyte Biotech Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| July 2024 | - | $32.64 M(-35.0%) |
| Apr 2024 | $50.18 M(-26.2%) | $50.18 M(-18.0%) |
| Jan 2024 | - | $61.21 M(-16.6%) |
| Oct 2023 | - | $73.43 M(-1.7%) |
| July 2023 | - | $74.66 M(+9.7%) |
| Apr 2023 | $68.04 M(-20.3%) | $68.04 M(-6.3%) |
| Jan 2023 | - | $72.64 M(-5.6%) |
| Oct 2022 | - | $76.96 M(-6.4%) |
| July 2022 | - | $82.23 M(-3.7%) |
| Apr 2022 | $85.40 M(+3778.1%) | $85.40 M(-1.4%) |
| Jan 2022 | - | $86.64 M(-0.3%) |
| Oct 2021 | - | $86.94 M(+8962.7%) |
| July 2021 | - | $959.30 K(-56.4%) |
| Apr 2021 | $2.20 M(+146.1%) | $2.20 M(-28.8%) |
| Jan 2021 | - | $3.09 M(-16.9%) |
| Oct 2020 | - | $3.72 M(+71.6%) |
| July 2020 | - | $2.17 M(+142.1%) |
| Apr 2020 | $894.90 K(+73.7%) | $894.90 K(+529.3%) |
| Jan 2020 | - | $142.20 K(+215.3%) |
| Oct 2019 | - | $45.10 K(-86.2%) |
| July 2019 | - | $327.80 K(-36.4%) |
| Apr 2019 | $515.30 K(-51.4%) | $515.30 K(-26.3%) |
| Jan 2019 | - | $699.50 K(-22.9%) |
| Oct 2018 | - | $907.40 K(-50.5%) |
| July 2018 | - | $1.83 M(+72.8%) |
| Apr 2018 | $1.06 M(-69.4%) | $1.06 M(-29.7%) |
| Jan 2018 | - | $1.51 M(-43.8%) |
| Oct 2017 | - | $2.68 M(-37.3%) |
| July 2017 | - | $4.28 M(+23.5%) |
| Apr 2017 | $3.46 M(+80.4%) | $3.46 M(+40.6%) |
| Jan 2017 | - | $2.46 M(+58.8%) |
| Oct 2016 | - | $1.55 M(-33.7%) |
| July 2016 | - | $2.34 M(+21.8%) |
| Apr 2016 | $1.92 M(-28.9%) | $1.92 M(-32.9%) |
| Jan 2016 | - | $2.86 M(+23.9%) |
| Oct 2015 | - | $2.31 M(-20.5%) |
| July 2015 | - | $2.91 M(+7.8%) |
| Apr 2015 | $2.70 M(-25.4%) | $2.70 M(+181.6%) |
| Jan 2015 | - | $958.80 K(-17.0%) |
| Oct 2014 | - | $1.16 M(-60.1%) |
| July 2014 | - | $2.90 M(-19.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Apr 2014 | $3.62 M(+1714.6%) | $3.62 M(+318.1%) |
| Jan 2014 | - | $864.90 K(+118.1%) |
| Oct 2013 | - | $396.60 K(+92.5%) |
| July 2013 | - | $206.00 K(+3.4%) |
| Apr 2013 | $199.30 K(+1169.4%) | $199.30 K(+498.5%) |
| Jan 2013 | - | $33.30 K(+46.7%) |
| Oct 2012 | - | $22.70 K(-6.6%) |
| July 2012 | - | $24.30 K(+54.8%) |
| Apr 2012 | $15.70 K(-72.6%) | $15.70 K(-59.8%) |
| Jan 2012 | - | $39.10 K(+169.7%) |
| Oct 2011 | - | $14.50 K(-82.6%) |
| July 2011 | - | $83.10 K(+45.3%) |
| Apr 2011 | $57.20 K(+8071.4%) | $57.20 K(+1488.9%) |
| Jan 2011 | - | $3600.00(>+9900.0%) |
| Oct 2010 | - | $0.00(-100.0%) |
| July 2010 | - | $500.00(-28.6%) |
| Apr 2010 | $700.00(-99.9%) | $700.00(+16.7%) |
| Jan 2010 | - | $600.00(-93.5%) |
| Oct 2009 | - | $9200.00(-83.5%) |
| July 2009 | - | $55.90 K(-90.7%) |
| Apr 2009 | $603.70 K(-60.1%) | $603.70 K(-37.0%) |
| Jan 2009 | - | $958.60 K(-21.0%) |
| Oct 2008 | - | $1.21 M(-9.8%) |
| July 2008 | - | $1.35 M(-11.1%) |
| Apr 2008 | $1.51 M(+36.5%) | $1.51 M(+34.3%) |
| Jan 2008 | - | $1.13 M(+77.5%) |
| Oct 2007 | - | $634.90 K(-41.8%) |
| July 2007 | - | $1.09 M(-1.7%) |
| Apr 2007 | $1.11 M(+3.8%) | $1.11 M(+30.9%) |
| Jan 2007 | - | $847.60 K(-24.9%) |
| Oct 2006 | - | $1.13 M(+13.3%) |
| July 2006 | - | $995.60 K(-6.9%) |
| Apr 2006 | $1.07 M(+2691.1%) | $1.07 M(+179.5%) |
| Jan 2006 | - | $382.50 K(+199.3%) |
| Oct 2005 | - | $127.80 K(+255.0%) |
| July 2005 | - | $36.00 K(-6.0%) |
| Apr 2005 | $38.30 K(-54.2%) | $38.30 K(-73.5%) |
| Jan 2005 | - | $144.60 K(-63.5%) |
| Oct 2004 | - | $396.70 K(-75.6%) |
| July 2004 | - | $1.63 M(+1845.5%) |
| Apr 2004 | $83.60 K | $83.60 K(+184.4%) |
| Jan 2004 | - | $29.40 K |
FAQ
- What is PharmaCyte Biotech annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for PharmaCyte Biotech?
- What is PharmaCyte Biotech annual cash & cash equivalents year-on-year change?
- What is PharmaCyte Biotech quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for PharmaCyte Biotech?
- What is PharmaCyte Biotech quarterly cash and cash equivalents year-on-year change?
What is PharmaCyte Biotech annual cash & cash equivalents?
The current annual cash & cash equivalents of PMCB is $50.18 M
What is the all time high annual cash & cash equivalents for PharmaCyte Biotech?
PharmaCyte Biotech all-time high annual cash & cash equivalents is $85.40 M
What is PharmaCyte Biotech annual cash & cash equivalents year-on-year change?
Over the past year, PMCB annual cash & cash equivalents has changed by -$17.86 M (-26.25%)
What is PharmaCyte Biotech quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of PMCB is $32.64 M
What is the all time high quarterly cash and cash equivalents for PharmaCyte Biotech?
PharmaCyte Biotech all-time high quarterly cash and cash equivalents is $86.94 M
What is PharmaCyte Biotech quarterly cash and cash equivalents year-on-year change?
Over the past year, PMCB quarterly cash and cash equivalents has changed by -$40.79 M (-55.55%)